Johanna Roberts Sells 600 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $269.11, for a total transaction of $161,466.00. Following the sale, the executive vice president now directly owns 66,353 shares in the company, valued at $17,856,255.83. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Johanna Roberts also recently made the following trade(s):

• On Monday, March 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $287.43, for a total value of $172,458.00.

Penumbra Trading Down 4.0 %

PEN opened at $262.37 on Friday. The firm’s fifty day moving average is $274.48 and its two-hundred day moving average is $245.21. The firm has a market cap of $10.11 billion, a PE ratio of 771.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. Equities research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Morgan Stanley raised their price objective on shares of Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 19th. Wells Fargo & Company boosted their price objective on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research report on Wednesday, February 19th. JPMorgan Chase & Co. boosted their target price on Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Finally, Truist Financial raised their price target on Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $294.47.

Institutional Trading of Penumbra

Several hedge funds and other institutional investors have recently modified their holdings of PEN. UMB Bank n.a. boosted its position in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after buying an additional 70 shares during the period. Hurley Capital LLC bought a new stake in Penumbra in the 4th quarter valued at approximately $56,000. Huntington National Bank boosted its position in Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after acquiring an additional 154 shares during the last quarter. Mather Group LLC. grew its stake in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after acquiring an additional 208 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Penumbra by 893.5% in the first quarter. Versant Capital Management Inc now owns 308 shares of the company’s stock valued at $82,000 after purchasing an additional 277 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.